Esophageal motility in systemic sclerosis before and after autologous hematopoietic cell transplantation

• Published in: Clinical rheumatology 2023-12, Vol.42 (12), p.3267-3274
• Main Authors: Woo, Matthew M. K., Levin, Daniel, Li, Dorothy Y., David, Joel, Buresi, Michelle, Gupta, Milli, Nasser, Yasmin, Andrews, Christopher N., Durand, Caylib, Osman, Mohammed S., Jamani, Kareem, Weatherald, Jason, Johannson, Kerri A., Howlett, Jonathan G., Hemmati, Iman, Kim, Hyein, Curley, Michael, Storek, Jan
• Format: Article
• Language: English
• Subjects: Autografts; cell transplantation; Contractility; Esophageal Motility Disorders - diagnosis; Esophagus; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Humans; lung function; Medicine; Medicine & Public Health; Morbidity; Motility; Original Article; Peristalsis; Recurrence; relapse; Respiratory function; Rheumatology; Scleroderma; Scleroderma, Systemic - complications; sclerosis; Stem cell transplantation; Systemic sclerosis
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-023-06766-7

Introduction Systemic sclerosis (SSc) is associated with esophageal dysmotility. Autologous hematopoietic cell transplantation (HCT) results in improvement of skin tightness and lung function. Whether esophageal motility improves after HCT is unknown. Methods Esophageal motility was studied using high-resolution esophageal manometry in 21 SSc patients before and at multiple time points after autologous HCT. Median posttransplant follow-up was 2 years (range, 6 months to 5 years). Results Prior to HCT, all 21 patients had abnormal motility—10 (48%) had unmeasurable and 11 (52%) had measurable peristalsis. Manometric diagnosis in the former 10 patients was “absent contractility” and in the latter 11 patients “ineffective esophageal motility (IEM).” After HCT, among the 10 patients with absent contractility, 9 continued to have absent contractility and one demonstrated weak measurable peristalsis. Of the 11 patients with IEM, 5 experienced SSc relapse, and 2 out of these 5 patients developed absent contractility. Among the 6 non-relapsed patients, 4 continued to have IEM, and 2 developed normal motility. Conclusions HCT appears to have no beneficial effect on motility in patients with unmeasurable peristalsis. In patients with measurable peristalsis, HCT appears to stabilize and in some normalize motility, unless relapse occurs. Key Points • In patients with systemic sclerosis, esophageal dysmotility is a significant contributor to morbidity and so far, there has been no data describing the effects of hematopoietic cell transplantation on esophageal motility. • Our work demonstrated that in patients with systemic sclerosis and unmeasurable esophageal peristalsis prehematopoietic cell transplantation, there was no measurable beneficial effect of transplantation on esophageal motility. • In patients with systemic sclerosis and measurable peristalsis prehematopoietic cell transplantation, esophageal motility stabilized, except in relapsed patients.